Molecular mechanisms of increased intrahepatic resistance in portal hypertension

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Shah, Vijay ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Nitric oxide; Portal hypertension; Vasoregulation

Indexed keywords

COLLATERAL CIRCULATION; CONFERENCE PAPER; FUNCTIONAL ANATOMY; HEMODYNAMICS; HEPATIC ARTERY; HUMAN; LIVER CIRRHOSIS; LIVER SINUSOID; MOLECULAR BIOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SHEAR STRESS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; COLLATERAL CIRCULATION; EXTRACELLULAR MATRIX; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRCULATION; PORTAL PRESSURE; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 35848965448     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318150d0e1     Document Type: Conference Paper

References (26)

1. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006;44:209-216.
2. Lee JS, Semela D, Iredale J, et al. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology. 2007;45:817-825.
3. Fernandez-Varo G, Ros J, Morales-Ruiz M, et al. Nitric oxide synthetase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol. 2003;162:1985-1993.
4. Rockey D, Shah V. Nitric oxide and the liver. Hepatology. 2004;39:250-257.
5. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental liver cirrhosis. Gastroenterology. 1999;117:1222-1228.
6. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344-351.
7. Gupta T, Toruner M, Chung M, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926-931.
8. Yokomori H, Oka M, Yoshimura K, et al. Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: relation with nitric oxide. J Gastroenterol. 2003;38:854-860.
9. Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125:522-531.
10. Liu S, Premont RT, Kontos CD, et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005;11:952-958.
11. Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007;45:62-71.
12. Laleman W, Omasta A, Van de Casteele M, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005;42:1382-1390.
13. Dudenhoefer A, Loureiro-Silva M, Cadelina G, et al. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology. 2002;36:381-385.
14. Perri RE, Langer DA, Chatterjee S, et al. Defects in cGMP-PKG pathway contribute to impaired NO dependent responses in hepatic stellate cells upon activation. Am J Physiol Gastrointest Liver Physiol. 2006;290:G535-G542.
15. Friedman SL, Rockey DC, McGuire RF, et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 1992;15:234-243.
16. Maher JJ, Bissell DM, Friedman SL, et al. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest. 1988;82:450-459.
17. Lee J, Decker N, Chatterjee S, et al. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol. 2005;166:1861-1870.
18. Daniels C, Wilkes M, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308-1316.
19. 2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology. 2006;131:1235-1252.
20. Anan A, Baskin-Bey ES, Bronk SF, et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology. 2006;43:335-344.
21. Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005;42:1339-1348.
22. Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126:3047-3055.
23. Straub AC, Stolz DB, Ross MA, et al. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology. 2007;45:205-212.
24. Zafra C, Abraldes J, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126:749-755.
25. Fiorucci S, Antonelli E, Tocchetti P, et al. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc Drug Rev. 2004;22:135-146.
26. Laleman W, Van Landeghem L, Van der Elst I, et al. Nitro-flurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132:709-719.